Design Therapeutics
DSGN
63 hedge funds and large institutions have $614M invested in Design Therapeutics in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 30 increasing their positions, 16 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
88% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 16
5% more funds holding
Funds holding: 60 → 63 (+3)
3.22% more ownership
Funds ownership: 64.98% → 68.21% (+3.2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
21% less capital invested
Capital invested by funds: $773M → $614M (-$159M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$14.3M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$8.98M |
| 3 |
Barclays
London,
United Kingdom
|
+$3.47M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.35M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$2.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$6.02M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.34M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.27M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$833K |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$328K |
DSGN Hedge Fund Activity: Q1 2022 in Review
63 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q1 2022, worth a combined $614M — down 21% from $773M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new DSGN positions and 3 closed out — a net gain of 3 holders — while 30 added to existing stakes and 16 trimmed.
The largest buyer was BlackRock, adding an estimated $14.3M. The largest seller was HHLR Advisors, exiting entirely with an estimated $6.02M sold.
- 63 institutional investors held Design Therapeutics (DSGN) as of Q1 2022, up from 60 in Q4 2021.
- Funds reported $614M of Design Therapeutics stock for Q1 2022, down 21% quarter-over-quarter.
- 6 funds opened new Design Therapeutics positions in Q1 2022 and 3 closed out, a net change of +3 holders.
- The largest Design Therapeutics buyer in Q1 2022 was BlackRock, an estimated $14.3M added.
- The largest Design Therapeutics seller in Q1 2022 was HHLR Advisors, an estimated $6.02M sold.
Based on aggregated 13F filings for Q1 2022.